A Decrease in Glucose Variability Does Not Reduce Cardiovascular Event Rates in Type 2 Diabetic Patients After Acute Myocardial Infarction: A reanalysis of the HEART2D study

Por Siegelaar, Sarah E., Kerr, Lisa, Jacober, Scott J., Devries, J. Hans
Publicado em 2011

Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes

Por de Leon, Ella M, Jacober, Scott J, Sobel, Jack D, Foxman, Betsy
Publicado em 2002

Dose Unit Establishment for a New Basal Insulin Using Joint Modeling of Insulin Dose and Glycemic Response

Por Qu, Yongming, Luo, Junxiang, Garhyan, Parag, Antalis, Caryl J., Chang, Annette M., Jacober, Scott J.
Publicado no J Diabetes Sci Technol (2017)

Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism

Por Moore, Mary Courtney, Smith, Marta S., Sinha, Vikram P., Beals, John M., Michael, M. Dodson, Jacober, Scott J., Cherrington, Alan D.
Publicado no Diabetes (2014)

Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia

Por Raz, Itamar, Ceriello, Antonio, Wilson, Peter W., Battioui, Chakib, Su, Eric W., Kerr, Lisa, Jones, Cate A., Milicevic, Zvonko, Jacober, Scott J.
Publicado em 2011

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes

Por Bergenstal, Richard M., Rosenstock, Julio, Arakaki, Richard F., Prince, Melvin J., Qu, Yongming, Sinha, Vikram P., Howey, Daniel C., Jacober, Scott J.
Publicado em 2012

Response to Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treate...

Por Bergenstal, Richard M., Rosenstock, Julio, Arakaki, Richard F., Prince, Melvin J., Qu, Yongming, Sinha, Vikram P., Howey, Daniel C., Jacober, Scott J.
Publicado em 2013

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

Por Rosenstock, Julio, Bergenstal, Richard M., Blevins, Thomas C., Morrow, Linda A., Prince, Melvin J., Qu, Yongming, Sinha, Vikram P., Howey, Daniel C., Jacober, Scott J.
Publicado em 2013

Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial

Por Raz, Itamar, Wilson, Peter W.F., Strojek, Krzysztof, Kowalska, Irina, Bozikov, Velimir, Gitt, Anselm K., Jermendy, György, Campaigne, Barbara N., Kerr, Lisa, Milicevic, Zvonko, Jacober, Scott J.
Publicado em 2009